MARKET

AKBA

AKBA

Akebia Therapeut
NASDAQ
0.6438
+0.0769
+13.57%
After Hours: 0.6400 -0.0038 -0.59% 19:47 10/26 EDT
OPEN
0.5878
PREV CLOSE
0.5669
HIGH
0.6754
LOW
0.5765
VOLUME
11.59M
TURNOVER
--
52 WEEK HIGH
3.200
52 WEEK LOW
0.5421
MARKET CAP
178.40M
P/E (TTM)
-5.8000
1D
5D
1M
3M
1Y
5Y
1D
Akebia Therapeutics Reports Data From Vafseo Outcomes In Center Experience Study At American Society Of Nephrology Kidney Week 2026 In Patients With Treated With Vadadustat
Benzinga · 12h ago
Weekly Report: what happened at AKBA last week (1019-1023)?
Weekly Report · 16h ago
Akebia Therapeutics, Inc. Receives Nasdaq Minimum Bid Price Deficiency Notice
NASDAQ · 3d ago
Akebia Therapeutics Faces Nasdaq Listing Compliance Challenge
TipRanks · 3d ago
Weekly Report: what happened at AKBA last week (1012-1016)?
Weekly Report · 10/19 09:41
Akebia Therapeutics Announces CCO Resignation and Advisory Role
TipRanks · 10/14 12:19
Weekly Report: what happened at AKBA last week (1005-1009)?
Weekly Report · 10/12 09:44
Weekly Report: what happened at AKBA last week (0928-1002)?
Weekly Report · 10/05 09:43
More
About AKBA
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). The Company's development pipeline includes mid-stage rare kidney disease pipeline assets (praliciguat and AKB-097) and early-stage pipeline assets (AKB-9090 and AKB-10108), which are HIF molecules.

Webull offers Akebia Therapeutics Inc stock information, including NASDAQ: AKBA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKBA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKBA stock methods without spending real money on the virtual paper trading platform.